ER
Erasca, Inc.
ERAS · NASDAQ
$15.34 -3.10% (-$0.49)
1M -15.14%
Market Cap $5.33B
P/E Ratio -
Div. Yield -
ROE 80.43%
Bulios Fair Price
$10.13
34.0% downside
Current Price
$15.34
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ERAS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 14.73x
P/FCF N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 7.57%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 66.02%
ROIC 37.52%
Debt
100 /100
Low Current ratio 8.29x
Debt/Equity 0.12x
Net debt/EBITDA N/A
Stability
74 /100
Stable EPS volatility 20.73%
Profitable years 0
Beta 0.65x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ERAS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jonathan E. Lim
Employees
103
Headquarters
San Diego
Upcoming events
11 NOV
Earnings
Upcoming earnings report